Maravai LifeSciences News and Resources

Maravai LifeSciences has officially completed its acquisition of Officinae Bio’s DNA and RNA business, expanding its expertise in mRNA design and drug substance manufacturing. The deal integrates Officinae Bio’s AI-enabled mRNA sequence-optimization platform with Maravai and its subsidiary TriLink BioTechnologies‘ manufacturing capabilities, supporting a streamlined

Maravai LifeSciences, announced it will acquire the DNA and RNA business of Officinae Bio, an Italy-based biotechnology company. This move aims to strengthen Maravai and its subsidiary, Trilink BioTechnologies, in advancing nucleic acid-based therapeutic development. Officinae Bio, headquartered in Venice,